The ‘claims’ on cannabis often reach legendary status, particularly as the pro-drug lobby hijack the market place communications and create ‘feeding frenzy’ headlines!
We have always said that a 140 character Tweet is mightier than 10,000 hard evidence-based research journals, in our current information rich, but knowledge poor social media culture!
This webpage Snake Oil Cannabis? Scientific evidence for the medical benefits Scientific evidence for the medical benefits, is at least one attempt to get some balance away from propaganda and hype of the ‘info-tainment’ that is passing as research news, which only continues to aid and abet the manufactured consensus around this plant!
We want to make perfectly clear that for the most part this info-graph is in concert with the current scientific evidence to date. However, at least one piece of data on the chart we know should be recategorized out of the ‘promising’ category to, at best, ‘INCONCLUSIVE’. The vast majority of the ‘data’ around cannabis impact on pain is at best anecdotal, and evidence from placebo trials are almost as effective on ‘pain’ as some cannabis formulations!
What is also very important to remember, if the product you are using is not Fully vetted, tested and trialled to FDA (Food & Drug Administration) and/or TGA (Therapeutic Goods Administration) and/or MHRA (Medicines and Healthcare Products Regulatory Agency) standards and registered as a pharmaceutical, it is NOT medicine, it is Snake Oil!
Whilst much research has focussed on the effects of endocannabinoids in the adult brain relatively little research has looked at the impact of these same effects in the developing brain of the foetus and neonate. Whilst the brain stem is almost devoid of type 1 cannabinoid receptors (CB1Rs) they are in high concentration in many parts of the midbrain, limbic system, subcortical regions and cerebral and cerebellar cortices 3. Foetal CB1Rs have been shown to play key roles in virtually all aspects of brain development including neural stem cell function, determining the ratio of glial v neuronal differentiation, brain inflammation, axonal growth cone guidance, stem cell niche function and signalling, blood flow signalling, white matter and CNS tract formation, glial cell differentiation, myelination, dendrite formation, neural migration into the developing cortex, synapse formation and integration of newly formed neurons into the neural network. They are also found in high density on endoplasmic reticulum and mitochondria from which latter they indirectly control major issues including cognition, DNA maintenance and repair systems both by supplying energy and by metabolite shuttle and RNA signalling 4 5.
Hence it is not surprising that gestational cannabis has been linked with a clear continuum of defects…
Men's Health October 18, 2018
Instead of endlessly ruminating on these hypothetical scenarios, I tested whether CBD supplements could help me relax and take my stress level down a notch. CBD, or Cannabidiol, is one of roughly 100 chemical compounds called cannabinoids found in the cannabis plant — and unlike its brother THC, it doesn't get you high. Among its many purported health benefits, researchers are studying whether CBD could be a viable treatment for a variety of ailments including anxiety.
The bottom line
Although the CBD tablets didn't work wonders for me, that's not to say that they can't help with anxiety. Anecdotally, many people on Reddit report feeling more relaxed and less anxious after taking CBD supplements.
But Dr. Margaret Haney, professor of neurobiology at the Columbia University Medical Center, warns that science doesn't yet support these claims.
"We’re in the infancy of cannabis science," she told MensHealth.com. When it comes to claims that CBD can help with pain, sleep, or anxiety, Haney warns that we're still waiting on the hard science. "As a society we’ve jumped very far ahead of our use of CBD. We don’t have any of the data, and we really struggle to understand where and how it’s doing anything."
This review examines evidence for the effectiveness of cannabinoids in chronic noncancer pain (CNCP) and addresses gaps in the literature by: considering differences in outcomes based on cannabinoid type and specific CNCP condition; including all study designs; and following IMMPACT guidelines. MEDLINE, Embase, PsycINFO, CENTRAL, and clinicaltrials.gov were searched in July 2017.
Analyses were conducted using Revman 5.3 and Stata 15.0. A total of 91 publications containing 104 studies were eligible (n = 9958 participants), including 47 randomised controlled trials (RCTs) and 57 observational studies. Forty-eight studies examined neuropathic pain, 7 studies examined fibromyalgia, 1 rheumatoid arthritis, and 48 other CNCP (13 multiple sclerosis–related pain, 6 visceral pain, and 29 samples with mixed or undefined CNCP).
Across RCTs, pooled event rates (PERs) for 30% reduction in pain were 29.0% (cannabinoids) vs 25.9% (placebo); significant effect for cannabinoids was found; number needed to treat to benefit was 24 (95% confidence interval [CI] 15-61); for 50% reduction in pain, PERs were 18.2% vs 14.4%; no significant difference was observed. Pooled change in pain intensity (standardised mean difference: −0.14, 95% CI −0.20 to −0.08) was equivalent to a 3 mm reduction on a 100 mm visual analogue scale greater than placebo groups. In RCTs, PERs for all-cause adverse events were 81.2% vs 66.2%; number needed to treat to harm: 6 (95% CI 5-8).
There were no significant impacts on physical or emotional functioning, and low-quality evidence of improved sleep and patient global impression of change. Evidence for effectiveness of cannabinoids in CNCP is limited. Effects suggest that number needed to treat to benefit is high, and number needed to treat to harm is low, with limited impact on other domains. It seems unlikely that cannabinoids are highly effective medicines for CNCP.